ArticleFrontiers in oncology2025
Establishment and validation of a prognostic model for nasopharyngeal carcinoma patients based on partial response rates.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aims to investigate the impact of varying rates of partial response (PR) on survival outcomes in nasopharyngeal carcinoma (NPC) patients following induction chemotherapy (IC) and to develop a nomogram for predicting overall survival (OS). Methods: Clinical data from 561 NPC patients with PR after IC at two institutions between 2014 and 2019 were analyzed using Cox regression. A nomogram was developed and assessed with the concordance index (C-index), calibration curves, Receiver Operating Characteristic (ROC) curves, and Decision Curve Analysis (DCA). Patients were stratified into risk groups based on nomogram scores, followed by the subgroup analyses. Results: Age, M stage, primary tumor volume post-IC, cervical lymph nodes volume post-IC, lymphocyte-to-monocyte ratio (LMR), and PR rate were independent OS predictor for NPC patients. The nomogram showed strong discrimination (C-index: 0.769) and outperformed TNM staging in predicting OS. The nomogram's risk scores effectively stratified patients into high- and low-risk groups, with low-risk patients had better OS, progression-free survival (PFS) and distant metastasis-free survival (DMFS). Subgroup analyses revealed a significant association between the cumulative dose of cisplatin chemotherapy and survival outcomes in patients with a PR rate below 49%. For those with a PR rate above 49%, cervical lymph nodes volume and the LMR were independent prognostic factors after IC. Conclusion: We developed and validated a nomogram that predicts the OS of NPC patients undergoing induction chemotherapy based on their PR rates. This tool helps clinicians forecast patient survival. Additionally, it provides valuable insights for optimizing treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.